Barusiban
![]() | |
| Systematic (IUPAC) name | |
|---|---|
|
(4S,7S,10S,13S,16R)-N-[(2S)-5-Amino-1-hydroxy-2-pentanyl]-7-(2-amino-2-oxoethyl)-10-[(2R)-2-butanyl]-13-sec-butyl-16-(1H-indol-3-ylmethyl)-N-methyl-6,9,12,15,18-pentaoxo-1-thia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide | |
| Identifiers | |
| CAS Number | 285571-64-4 |
| ATC code | None |
| PubChem | CID 9832431 |
| ChemSpider | 8008159 |
| Chemical data | |
| Formula | C40H63N9O8S |
| Molar mass | 830.049 g/mol |
| |
| |
Barusiban (INN) (code name FE-200440) is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known.[1][2] It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further.[1][3]
See also
References
- 1 2 Rainer Landgraf; Inga D. Neumann (10 September 2008). Advances in Vasopressin and Oxytocin - From Genes to Behaviour to Disease. Elsevier. pp. 194,489. ISBN 978-0-08-093247-7.
- ↑ Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 1278–. ISBN 978-3-540-38916-3.
- ↑ Richard Ouellette; Joseph Joyce (25 October 2010). Pharmacology for Nurse Anesthesiology. Jones & Bartlett Publishers. pp. 450–. ISBN 978-0-7637-8607-6.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
